Physician profile
Matthew Wright
NPI 1164886701
$3,254.75
in general payments reported to CMS, 2019-2025
15 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $85.44 · 2021: $221 · 2022: $1,083 · 2023: $917 · 2024: $374 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.15 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $502.49 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $485.12 | 2023-2025 | Datroway, Enhertu, Lynparza |
| Seagen INC. | $348.86 | 2022 | |
| Astellas Pharma US INC | $314.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $246.89 | 2022 | |
| Incyte Corporation | $241.85 | 2021-2022 | |
| Daiichi Sankyo INC. | $238.23 | 2024-2025 | Enhertu |
| Gen-Probe, INC. | $149.67 | 2023 | Btx |
| Avita Medical Americas, LLC | $147.85 | 2023 | Recell |
| Puma Biotechnology, INC. | $124.48 | 2025 | |
| Stemline Therapeutics INC. | $121.85 | 2023 | Orserdu |
| Lilly USA, LLC | $119.74 | 2023 | Verzenio |
| Jazz Pharmaceuticals INC. | $111.75 | 2021 | |
| Celgene Corporation | $85.44 | 2020 | |
| Biogen, INC. | $15.56 | 2023 | Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.